Skip to main content

A new approach to multiple myeloma

Advertisement

In multiple myeloma (MM), bone marrow cells become malignant, leading to a weakened immune system, kidney failure, severe bone loss and consequent fractures. Although treatment options have improved significantly thanks to new drugs such as lenalidomide and pomalidomide, the tumour eventually develops resistance to treatment and continues to grow despite therapy. Using comprehensive protein analyses (proteomics), a German research team has now unravelled a previously unknown mechanism by which such a relapse can occur. “We were able to show that the cell division regulator CDK6 is produced in excessively high quantities by the cancer cells at the point when resistance to treatment develops,” explains Jan Krönke of Charité Campus Benjamin Franklin. The abbreviation stands for Cyclin-Dependent Kinase 6 and refers to an enzyme that regulates the initiation of cell division within the cell. More than 6,000 different proteins were analysed in tumour samples taken from patients before and after a relapse. The fact that CDK6 plays a central role in the development of resistance to treatment was initially demonstrated in cell cultures. When the level of CDK6 in cultured myeloma cells was increased, the cells became resistant to the drugs lenalidomide and pomalidomide. However, when a CDK6 inhibitor was added, the treatments became effective again and the cancer cells were destroyed. This effect was also confirmed in an animal model. “The data suggest that even patients with treatment-resistant MM could benefit from additional CDK6 inhibition,” said Krönke. Further studies are now planned to clarify this, and the researchers have another advantage on their side, as some CDK6 inhibitors are already approved for the treatment of breast cancer. Evelyn Ramberger, the study’s second first author, said: “In future, we want to pursue this new approach in other cancers to identify therapeutic targets and biomarkers for personalised cancer medicine.” Reference: Charité Berlin, MDC Munich. ‘Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma’, Nature Communications 2022; https://www.nature.com/articles/s41467-022-28515-1

#cancer #haematology #multiplemyeloma #bloodcancer #tumour #cancertreatment #lenalidomide #medicine #medimpressions

  • Author

    Gernot Hofer

More on this topic
Hormones

Low testosterone in men: symptoms, causes and treatment

Fatigue, a reduced sex drive, and a lack of energy: these symptoms can have many causes. One possible explanation is a testosterone deficiency. However, it is not possible to determine whether testosterone levels are actually too low based solely on the symptoms or on a single blood test result.

Men's health
Men's health

PSA level: What does it mean, and when is it too high?




The PSA level is one of the best-known laboratory test results relating to the prostate. Many men come across it for the first time during a screening examination or when having symptoms investigated. An abnormal result often raises questions: Is this already a sign of prostate cancer? What levels are considered normal?

Prostate
Pollen allergy

The right diet for hay fever

Anyone suffering from hay fever should pay particular attention to their diet so as not to make the symptoms any worse.

Nutrition
Urology

Prostate health: What men need to know

The prostate is a gland in a man’s body that is only the size of a chestnut, but it plays a crucial role in well-being, urinary function and male sexuality. Benign enlargement and prostate cancer become more common in older age.

Prostate